Phase 1 N=17 tTF-NGR Phase I Study
Malignant Solid Tumors · Lymphomas
Primary: Maximum Tolerated Dose (MTD) and Dose-limiting Toxicity (DLT) — 8; 5; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=129 Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee
Osteoarthritis, Knee
Primary: Mean Standardized Change in Synovial Volume (SV) at 6 Weeks — -0.67; -0.9 Standardized Units
N/A N=134 Evaluation of Methods for Implementation of a Comfort Care Order Set
Terminal Conditions, End of Life
Primary: Presence of an Active Opioid Order at Time of Death — 1330; 1543 Participants — p=0.445
Phase 1 N=190 A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.
Healthy Volunteers
Primary: Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) of SHP643 in Plasma — 348.9; 376.5 day*microgram per…
Phase 2 N=256 Effects of Delayed Cord Clamp and/or Indomethacin on Preterm Infant Brain Injury
Intraventricular Hemorrhage · Periventricular Leukomalacia · Brain Injury
Primary: Percent of Survivors With no Severe IVH (Grades 3 or 4) or PVL — 22.2; 14.9; 17.1; 10.9 percent of participants
N/A N=40 The Effects of Neurodevelopmental Therapy on Feeding and Swallowing.
Cerebral Palsy
Primary: Gross Motor Function Classification System (GMFCS) — 4; 2; 0; 0 Participants
N/A N=442 Case Collection Study to Support Digital Mammography Image Software Change
Breast Cancer
Primary: Area Under the Receiver Operating Characteristic (ROC) Curve to Compare Diagnostic Accuracy of 2 Algorithms in Breast Cancer Diagnosis — 0.884; 0.880 probability
Phase 2 N=40 Research Investigation of Soy and Estrogen
Menopause · Hot Flashes
Primary: Change in STAI-6 Score — 12.31; 11.85; 10.76; 11.69 score on STAI scale — p=.004
Phase 1 N=7 Autologous Fecal Microbiota Transplantation to Prevent Antibiotic Resistant Bacteria Colonization
Antibiotic Resistant Strain
Primary: Number of Participants With Adverse Events (NIH Grade ≥2) at Day 7 After Randomization — 4; 0 Participants
Phase 2 N=67 PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting
Chemotherapy-induced Nausea and Vomiting (CINV)
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Netupitant — 4460; 3849; 17340; 7637 ng*hr/mL
N/A N=35 IFC Therapy in Proximal Humerus Fractures
Interferential Current in Proximal Humerus Fractures
Primary: Constant-Murley Score — 57.0; 48.2; 69.0; 60.7 score on a scale
N/A N=30 Impact of Nutritional Supplementation on Aerobic Performance and Fatigue
Performance · Fatigue
Primary: Perceived Exertion — 6.7; 7.4 units on a scale
N/A N=30 Personalised HTO Versus Generic HTO Virtual Clinical Trial
Osteoarthritis, Knee
Primary: Mechanical Stress in Plate During Gait — 108.3; 90.6 MPa
Phase 2 N=29 Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Median Time to Progression (TTP) — 3.7 months
Phase 2 N=96 Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma
Relapsed/Refractory Classical Hodgkin's Lymphoma
Primary: Objective Response Rate (ORR) Assessed According to the Revised International Working Group Response Criteria for Malignant Lymphoma in 2007(IWG 2007) by the Independent…